**antibody investigator sheet and order form**

**Process Overview**

1. The first step of the process is to have a *Material Transfer Agreement* in place between the ordering institution and the University of North Carolina – Chapel Hill. The MTA can be found on the website. Please send a completed and signed copy of the MTA to Tim Jensen at tjensen@med.unc.edu.
2. Once an MTA is in place please forward a completed Order Form (Appendix A) to Tim Jensen at tjensen@med.unc.edu. A completed order form must have the following:
	1. A correct address for shipments, many shipping companies will not deliver to PO Boxes.
	2. Shipping account number to cover the cost of shipment.
	3. Purchase Order number to cover the cost of ordering the antibodies at $60 per vial – or – a wire transfer.
3. All completed orders received by 12:00 pm Eastern, Thursday will be processed the following Tuesday for shipment. Incomplete orders may incur a delay.

***Please Note:***

In any correspondence please list the requesting institution as well as investigator; this will help keep track of the various orders, especially if correspondence originates from multiple departments in the requesting institution.

Antibody orders are subject to approval by CFF and approved orders are filled on a first come, first serve basis.

**By submitting this application packet, the requestor agrees to the following:**

* **A $60 fee will be charged for each vial .** The fee must be paid through Purchase Order (PO) from your University, Institution or Company or via wire transfer. The total charged fee must be received before a second order will be considered. If paying by wire transfer, an extra $25 will be added to the invoice to cover bank fees.
* You will be responsible for the cost of the shipping via your University, Institution or Company’s FedEx/Courier account.
* At any time after receipt of the antibodies you may be asked to complete a report. CFF reserves the right to post data from these reports in a public web site describing these antibodies.
* CFF makes no claims regarding these antibodies, including the utility or fitness for a particular purpose.
* Please acknowledge Martina Gentzsch, Ph.D., University of North Carolina – Chapel Hill, and Cystic Fibrosis Foundation within each of your manuscripts or public presentations demonstrating data generated using the antibodies received through this program. Please send a copy of each manuscript to Katherine Tuggle, Ph.D. at CFF (ktuggle@cff.org).
* Wire Transfer fees are the responsibility of the ordering party.

**Please make payments payable to:**

UNC Antibody Distribution Program, Attention: Kym Thacker

Genetic Medicine Building

125 Mason Farm Rd, CB7248 Rm 7011

Chapel Hill, NC 27599

**appendix a: antibody order form**

|  |  |
| --- | --- |
| Order Form |  |
| Company or Institution: |  |
| Principal Investigator:  |  |
| Contact:  |  |
| Contact Phone Number:  |  |
| Contact Fax Number:  |  |
| Contact Email:  |  |
| Shipping Address:  |  |
| Billing Address & email: |  |
| FedEx Shipping Number:  |  |
| PO#: |  |
| Wire Transfer: |  |
| Economic Operator Registration and Identification (EORI) number (EU Country orders) |  |
|  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antibody  Name** | **Notes** | **Related Reference** |  | **Vial Quantity****($60/vial)** |
| 660 | Class: IgG2b Suggested Dilutions:Western Blot : 1:500 to 1:2000Cytochemistry : TBDDomain Recognized: **NBD1 aa 576-585**  | 1 |  |  |
| 570 | Class: IgG1 Suggested Dilutions:Western Blot : 1:1000 to 1:5000 Cytochemistry : 1:250-1:1000Domain Recognized: ***R Domain* aa 731-742** | 1,3,4,7,8 |  |  |
| 570P | Antibody 570 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 217 | Class: IgG1 Suggested Dilutions:Western Blot : 1:1000 to 1:5000 Cytochemistry : TBD Domain Recognized: ***R Domain* aa 807-819**  | 1,7,8 |  |  |
| 217P | Antibody 217 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 596 | Class: IgG2b Suggested Dilutions:Western Blot : 1:1000 to 1:5000 Cytochemistry : 1:250 Domain Recognized: **NBD2 aa1204-1211** | 1-9 |  |  |
| 596P | Antibody 596 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 769 | Class: IgG1 Suggested Dilutions: Western Blot : 1:1000 to 1:5000 Cytochemistry : 1:250 Domain Recognized: **NBD2 aa1204-1211**  | 7,8 |  |  |
| 450 | Class: IgG1 Suggested Dilutions:Western Blot : 1:1000 to 1:5000Cytochemistry : 1:250 Domain Recognized: **R Domain aa 696-705** | 10 |  |  |
| 450P | Antibody 450 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 432 | Class: IgG1 Suggested Dilutions:Western Blot : 1:1000 to 1:5000Cytochemistry : 1:250 Domain Recognized: ***R Domain* aa 762-770** |   |   |  |
| 154 | Class: IgG2a Cytochemistry : TBDDomain Recognized**:** **RI of NBD1 aa 405-436** |  |  |  |
| 154P | Antibody 154 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 528 | Class: IgG1 Cytochemistry : 1:250-1:1000Western Blot : 1:1000 to 1:5000Domain Recognized:**NBD2 aa 1204-1211**  |  |  |  |
| 8H16 | Class:Cytochemistry:Western Blot: 1:250Domain Recognized: **R Domain** **aa 648-657**  |  |  |  |
| 1I22 | Class: IgG 2bCytochemistry:Western Blot: 1:1000Domain Recognized: **R Domain** **aa 668-675**  |  |  |  |
| TJA9 | Class: IgG 1Cytochemistry: Not testedWestern Blot: 1:500Domain Recognized: **EL1 aa 106-116** |  |  |  |
| TJA9P | Antibody TJA9 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 1D9 | Class: IgG1Western Blot: 1:1000Domain Recognized:**Lasso region aa 46-60** |  |  |  |
| 1D9P | Antibody 1D9 purified 50 g in 100 l TBS+50% glycerol with azide as preservative |  |  |  |
| 5E2 | Class: IgG1Western Blot: 1:1000Domain Recognized: **C-terminus aa 1371-1385** |  |  |  |
| Positive Control lysate | Lysate from BHK cells expressing CFTREach vial contains 100 l lysate in sample buffer.Use 5-10 l per lane |  |  |  |
| Negative Control lysate | Lysate from BHK cells.Each vial contains 100 l lysate in sample buffer.Use 5-10 l per lane |  |  |  |

* Antibody lots are submitted to Quality Control to confirm usage indicated.
* Each Antibody is a mouse monoclonal antibody produced by immunizing with purified human CFTR protein.
* To request an antibody, please mark the "Quantity" column with the number of vials requested.

**appendix b: references**

1. Cui L, Aleksandrov L, Chang X B, Hou Y X, He L, Hegedus T, Gentzsch M, Aleksandrov A, Balch W E, and Riordan JR (2007). "Domain interdependence in the biosynthetic assembly of CFTR". Journal of Molecular Biology 365 (4): 981-94

2. Gentzsch M, Choudhury A, Chang X B, Pagano R E and Riordan (2007)."Misassembled mutant {Delta}F508 CFTR in the distal secretory pathway alters cellular lipid trafficking."J Cell Sci **120**(Pt 3): 447-55

3. Gentzsch M, Cui L, Mengos A, Chang X B, Chen J H and Riordan J R (2003). "The PDZ-binding chloride channel ClC-3B localizes to the Golgi and associates with cystic fibrosis transmembrane conductance regulator-interacting PDZ proteins."J Biol Chem **278**(8): 6440-9.

4. Gentzsch M, Chang X B, Cui L, Wu Y, Ozols V V, Choudhury A, Pagano R E and Riordan J R (2004). "Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator." Mol Biol Cell **15**(6): 2684-96.

5. Grubb B R, Gabriel S E, Mengos A, Gentzsch M, Randell S H, Van Heeckeren A M, Knowles M R, Drumm M L, Riordan J R and Boucher R C (2006). "SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis." Am J Respir Cell Mol Biol **34**(3): 355-63.

6. Hegedus T, Aleksandrov A, Cui L, Gentzsch M, Chang X B and Riordan JR (2006)."F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive." Biochim Biophys Acta **1758**(5): 565-72.

7. Kreda S M, Mall M, Mengos A, Rochelle L, Yankaskas J, Riordan J R and Boucher R C (2005). "Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. "Mol Biol Cell **16**(5): 2154-67.

8. Mall M, Kreda S M, Mengos A, Jensen T J, Hirtz S, Seydewitz H H, Yankaskas J, Kunzelmann K, Riordan J R and Boucher R C (2004). "The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon.” Gastroenterology **126**(1): 32-41.

9. Malmberg E K, Andersson C X, Gentzsch M, Chen J H, Mengos A, Cui L, Hansson G C and Riordan J R (2004). "Bcr (breakpoint cluster region) protein binds to PDZ-domains of scaffold protein PDZK1 and vesicle coat protein Mint3.” J Cell Sci **117**(Pt 23): 5535-41

10. He L, Aleksandrov AA, Serohijos AW, Hegedus T, Aleksandrov LA, Cui L, Dokholyan NV, Riordan JR.(2008) "Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating". J.Biol Chem. Sept 26 **283 (39):26383-90. Epub 2008 Jul 25.**